395 related articles for article (PubMed ID: 31292270)
1. Emergence of
Subramanian J; Katta A; Masood A; Vudem DR; Kancha RK
Oncologist; 2019 Dec; 24(12):e1303-e1314. PubMed ID: 31292270
[TBL] [Abstract][Full Text] [Related]
2. Oncogenic alterations in ERBB2/HER2 represent potential therapeutic targets across tumors from diverse anatomic sites of origin.
Chmielecki J; Ross JS; Wang K; Frampton GM; Palmer GA; Ali SM; Palma N; Morosini D; Miller VA; Yelensky R; Lipson D; Stephens PJ
Oncologist; 2015 Jan; 20(1):7-12. PubMed ID: 25480824
[TBL] [Abstract][Full Text] [Related]
3. Targeting ERBB2 mutations in solid tumors: biological and clinical implications.
Cousin S; Khalifa E; Crombe A; Laizet Y; Lucchesi C; Toulmonde M; Le Moulec S; Auzanneau C; Soubeyran I; Italiano A
J Hematol Oncol; 2018 Jun; 11(1):86. PubMed ID: 29941010
[TBL] [Abstract][Full Text] [Related]
4. Intrinsic Subtype Switching and Acquired ERBB2/HER2 Amplifications and Mutations in Breast Cancer Brain Metastases.
Priedigkeit N; Hartmaier RJ; Chen Y; Vareslija D; Basudan A; Watters RJ; Thomas R; Leone JP; Lucas PC; Bhargava R; Hamilton RL; Chmielecki J; Puhalla SL; Davidson NE; Oesterreich S; Brufsky AM; Young L; Lee AV
JAMA Oncol; 2017 May; 3(5):666-671. PubMed ID: 27926948
[TBL] [Abstract][Full Text] [Related]
5. The predictive role of ERBB2 point mutations in metastatic colorectal cancer: A systematic review.
Vaghi C; Mauri G; Agostara AG; Patelli G; Pizzutilo EG; Nakamura Y; Yoshino T; Siena S; Sartore-Bianchi A
Cancer Treat Rev; 2023 Jan; 112():102488. PubMed ID: 36410093
[TBL] [Abstract][Full Text] [Related]
6. Next-Generation Assessment of Human Epidermal Growth Factor Receptor 2 (ERBB2) Amplification Status: Clinical Validation in the Context of a Hybrid Capture-Based, Comprehensive Solid Tumor Genomic Profiling Assay.
Ross DS; Zehir A; Cheng DT; Benayed R; Nafa K; Hechtman JF; Janjigian YY; Weigelt B; Razavi P; Hyman DM; Baselga J; Berger MF; Ladanyi M; Arcila ME
J Mol Diagn; 2017 Mar; 19(2):244-254. PubMed ID: 28027945
[TBL] [Abstract][Full Text] [Related]
7. ERBB2 mutation frequency in lobular breast cancer with pleomorphic histology or high-risk characteristics by molecular expression profiling.
Christgen M; Bartels S; Radner M; Raap M; Rieger L; Christgen H; Gluz O; Nitz U; Harbeck N; Lehmann U; Kreipe H
Genes Chromosomes Cancer; 2019 Mar; 58(3):175-185. PubMed ID: 30520184
[TBL] [Abstract][Full Text] [Related]
8. High-Throughput Functional Evaluation of Variants of Unknown Significance in
Nagano M; Kohsaka S; Ueno T; Kojima S; Saka K; Iwase H; Kawazu M; Mano H
Clin Cancer Res; 2018 Oct; 24(20):5112-5122. PubMed ID: 29967253
[No Abstract] [Full Text] [Related]
9. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
Roskoski R
Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
[TBL] [Abstract][Full Text] [Related]
10. Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer.
Meric-Bernstam F; Johnson AM; Dumbrava EEI; Raghav K; Balaji K; Bhatt M; Murthy RK; Rodon J; Piha-Paul SA
Clin Cancer Res; 2019 Apr; 25(7):2033-2041. PubMed ID: 30442682
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic Potential of Afatinib for Cancers with
Yamamoto H; Toyooka S; Ninomiya T; Matsumoto S; Kanai M; Tomida S; Kiura K; Muto M; Suzawa K; Desmeules P; Kris MG; Li BT; Ladanyi M
Oncologist; 2018 Feb; 23(2):150-154. PubMed ID: 29146616
[TBL] [Abstract][Full Text] [Related]
12. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
Ross JS; Gay LM; Wang K; Ali SM; Chumsri S; Elvin JA; Bose R; Vergilio JA; Suh J; Yelensky R; Lipson D; Chmielecki J; Waintraub S; Leyland-Jones B; Miller VA; Stephens PJ
Cancer; 2016 Sep; 122(17):2654-62. PubMed ID: 27284958
[TBL] [Abstract][Full Text] [Related]
13. Integrated genomic and transcriptomic analysis of human brain metastases identifies alterations of potential clinical significance.
Saunus JM; Quinn MC; Patch AM; Pearson JV; Bailey PJ; Nones K; McCart Reed AE; Miller D; Wilson PJ; Al-Ejeh F; Mariasegaram M; Lau Q; Withers T; Jeffree RL; Reid LE; Da Silva L; Matsika A; Niland CM; Cummings MC; Bruxner TJ; Christ AN; Harliwong I; Idrisoglu S; Manning S; Nourse C; Nourbakhsh E; Wani S; Anderson MJ; Fink JL; Holmes O; Kazakoff S; Leonard C; Newell F; Taylor D; Waddell N; Wood S; Xu Q; Kassahn KS; Narayanan V; Taib NA; Teo SH; Chow YP; kConFab ; Jat PS; Brandner S; Flanagan AM; Khanna KK; Chenevix-Trench G; Grimmond SM; Simpson PT; Waddell N; Lakhani SR
J Pathol; 2015 Nov; 237(3):363-78. PubMed ID: 26172396
[TBL] [Abstract][Full Text] [Related]
14. Molecular Landscape of
Wang H; Miao J; Wen Y; Xia X; Chen Y; Huang M; Chen S; Zhao Z; Zhang Y; Chen C; Zhu X
Pathol Oncol Res; 2022; 28():1610360. PubMed ID: 35911441
[No Abstract] [Full Text] [Related]
15. Mutations in the Kinase Domain of the HER2/ERBB2 Gene Identified in a Wide Variety of Human Cancers.
Wen W; Chen WS; Xiao N; Bender R; Ghazalpour A; Tan Z; Swensen J; Millis SZ; Basu G; Gatalica Z; Press MF
J Mol Diagn; 2015 Sep; 17(5):487-95. PubMed ID: 26320869
[TBL] [Abstract][Full Text] [Related]
16. Detection of
Lee J; Franovic A; Shiotsu Y; Kim ST; Kim KM; Banks KC; Raymond VM; Lanman RB
Front Oncol; 2019; 9():212. PubMed ID: 31019892
[No Abstract] [Full Text] [Related]
17. Activating Mutations in ERBB2 and Their Impact on Diagnostics and Treatment.
Herter-Sprie GS; Greulich H; Wong KK
Front Oncol; 2013; 3():86. PubMed ID: 23630663
[TBL] [Abstract][Full Text] [Related]
18. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.
Shea M; Costa DB; Rangachari D
Ther Adv Respir Dis; 2016 Apr; 10(2):113-29. PubMed ID: 26620497
[TBL] [Abstract][Full Text] [Related]
19. HER2 in solid tumors: more than 10 years under the microscope; where are we now?
Martin V; Cappuzzo F; Mazzucchelli L; Frattini M
Future Oncol; 2014 Jun; 10(8):1469-86. PubMed ID: 25052756
[TBL] [Abstract][Full Text] [Related]
20. Genetic screening and molecular characterization of MET alterations in non-small cell lung cancer.
Saigi M; McLeer-Florin A; Pros E; Nadal E; Brambilla E; Sanchez-Cespedes M
Clin Transl Oncol; 2018 Jul; 20(7):881-888. PubMed ID: 29139039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
